Table 1.
Basic characteristics of patients in the included studies.
| Author | Year | Study design | Arms | Subjects | Age | Female% | IDH Mutated | MGMT Methylated | KPS | WHOPS | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Heiland | 2016 | RS | Lom + Bev | 18 | 50 | 50% | 2/18 | 4/18 | ≥60 | NR | Median OS Median PFS |
| Bev | 17 | 39.5 | 41% | 3/17 | 6/17 | ||||||
| Weathers | 2016 | RCT | Lom + Bev | 35 | 53.32 | 67% | NR | NR | ≥60 | NR | Median OS Median PFS 6-month PFS |
| Bev | 36 | 53.86 | 69% | NR | NR | ||||||
| Brandes | 2019 | RCT | Lom + Bev | 61 | 56 | 28% | NR | 11/61 | ≥60 | NR | Median OS Median PFS |
| Lom + Placebo | 62 | 58.5 | 27% | NR | 12/62 | ≥50 | |||||
| Taal | 2014a | RCT | Lom + Bev | 22 | 58 | 32% | 2/20 | 10/21 | NR | 0–2 | Median OS Median PFS 6-month PFS |
| Bev | 50 | 58 | 36% | 1/39 | 18/42 | ||||||
| Taal | 2014b | RCT | Lom + Bev | 22 | 58 | 32% | 2/20 | 9/20 | NR | 0–2 | Median OS Median PFS 6-month |
| Lom | 46 | 56 | 43% | 3/42 | 23/43 | ||||||
| Jakobsen | 2018 | PS | Lom + Bev | 70 | 62 | 37.10% | NR | NR | NR | 0–2 | Median OS Median PFS |
| Bev + Iri | 219 | 56 | 33.30% | NR | NR | ||||||
| Wick | 2017 | RCT | Lom + Bev | 288 | 57.1 | 39.60% | NR | 67/288 | NR | 0–2 | Median OS Median PFS |
| Lom | 149 | 59.8 | 38.90% | NR | 37,149 |
IDH, isocitrate dehydrogenase; MGMT,O6-methylguanine-DNA-methyltransferase;KPS, Karnofsky Performance Status; WHOPS, World Health Organization performance status; RS, retrospective study; RCT, randomized controlled trial; PS, prospective study; Lom, lomustine; Bev, bevacizumab; NR, not report.